Put companies on watchlist
M1 Kliniken AG
ISIN: DE000A0STSQ8
WKN: A0STSQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

M1 Kliniken AG · ISIN: DE000A0STSQ8 · EQS - Company News (68 News)
Country: Germany · Primary market: Germany · EQS NID: 1774715
16 November 2023 08:56AM

Further strong growth and doubling of the operating result


EQS-News: M1 Kliniken AG / Key word(s): 9 Month figures/Quarter Results
M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

16.11.2023 / 08:56 CET/CEST
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG publishes figures for the third quarter 2023:

Further strong growth and doubling of the operating result    

 
  • Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).
     
  • Group EBITDA increases by over 55% from EUR 10.9 million to EUR 16.9 million.
     
  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).
     
  • Beauty segment: sales increase of 28.5% to EUR 53.2 million (previous year: EUR 41.4 million) and sharp rise in the Beauty EBIT margin from 8.2% to 23.5%

Berlin, 16 November 2023 – M1 Kliniken AG (ISIN: DE000A0STSQ8) announces the unaudited IFRS financial figures for the period January to September 2023. Accordingly, the consolidated sales of the M1 Group increased by 10.5% to EUR 236.6 million in the first nine months of 2023 (previous year: EUR 214.2 million).
The M1 Group's consolidated EBITDA totalled EUR 16.9 million as of 30 September 2023 (previous year: EUR 10.9 million), which corresponds to an increase of 55.4 %. EBIT rose by 98.2% to EUR 12.94 million (previous year: EUR 6.53 million), an increase of EUR 6.4 million. The Group EBIT margin increased from 3.0% to 5.5%.
Sales and EBIT in the Beauty segment increased disproportionately in the first nine months of 2023. Sales increased by 28.5% to EUR 53.2 million (previous year: EUR 41.4 million). Four new aesthetic specialist centres were opened in Germany and abroad in the reporting period. The number of locations thus rose to a total of 58 medical treatment centres. EBIT in this segment improved from EUR 3.4 million to EUR 12.5 million. The EBIT margin in the Beauty segment increased from 8.2% to 23.5%.
The international beauty markets achieved sales growth of almost 100% to over EUR 11.4 million (previous year: EUR 6.0 million) and positive EBIT of EUR 0.3 million for the first time (previous year: EUR -1.1 million), thereby breaking even.
Further new specialist centres are being prepared for opening in Germany and abroad.


"Our expansion activities are fully on track and we expect to be able to open two more new locations in the current financial year, meaning that the M1 network will comprise 60 locations by the end of the year. The importance of foreign locations will increase considerably in the future. To this end, the Group is investing in brand awareness and reach in the national markets it serves," says Attila Strauss, CEO of M1 Kliniken AG.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand name "M1 Med Beauty", beauty medical treatments are currently offered at 58 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its internationalisation and is currently represented in nine countries. With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.



Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


16.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1774715

 
End of News EQS News Service

1774715  16.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1774715&application_name=news&site_id=boersengefluester_html
Visual performance / price development - M1 Kliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.